# EDGAR Filing Document

**Accession Number:** 0001827087
**File Stem:** 0001193125-23-032542
**Filing Date:** 2023-2
**Character Count:** 5059
**Document Hash:** 6058fe4e8817b9a91b4c00c9e27cb4ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-032542.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0001193125-23-032542

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230208

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vigil Neuroscience, Inc.
- **CENTRAL INDEX KEY:** 0001827087
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41200
- **FILM NUMBER:** 23611806

**BUSINESS ADDRESS:**
- **STREET 1:** 100 FORGE ROAD
- **STREET 2:** SUITE 700
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-254-4445

**MAIL ADDRESS:**
- **STREET 1:** 100 FORGE ROAD
- **STREET 2:** SUITE 700
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): February 8, 2023

------

## VIGIL NEUROSCIENCE, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41200** | **85-1880494** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| |
|:---|
| **Vigil Neuroscience, Inc.** |
| **100 Forge Rd, Suite 700, Watertown, MA 02472** |
| **(Address of principal executive offices, including zip code)** |

---

(857) 254-4445

#### (Registrant's telephone number, including area code)

#### 1 Broadway, 7th Floor, Suite 07-300

#### Cambridge, Massachusetts, 02142

#### (Former Name or Former Address, if Changed Since Last Report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trade**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.0001 par value per share | VIGL | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 8, 2023, Shaan Gandhi, MD, PhD, MBA, notified Vigil Neuroscience, Inc. ("**Vigil**") of his resignation as a member of Vigil's board of directors (the "**Board**"), effective as of February 10, 2023, where he serves as a Class I director and member of the Audit and Compensation Committees. Dr. Gandhi's resignation is because he has accepted employment with a third party, the terms of which do not permit service as a board member of any company. Dr. Gandhi's resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. The Company thanks Dr. Gandhi for his substantial contributions as a founding Board member and wishes him well in his future endeavors.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Vigil Neuroscience, Inc. | Vigil Neuroscience, Inc. |
| Date: February 10, 2023 | By: | /s/ Ivana Magovčević-Liebisch |
|  |  | Ivana Magovčević-Liebisch |
|  |  | President and Chief Executive Officer |

---